BPG is committed to discovery and dissemination of knowledge
Featured Articles
2/15/2023 10:56:12 AM | Browse: 561 | Download: 1774
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 81600
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models
Manuscript Source Unsolicited Manuscript
All Author List Xin-Mo Liu, Shao-You Xia, Wei Long, Hai-Jun Li, Gui-Qun Yang, Wen Sun, Song-Yan Li and Xiao-Hui Du
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 81871317
Corresponding Author Xiao-Hui Du, MD, Chief Doctor, Deputy Director, Professor, Department of General Surgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100039, China. duxiaohuiplagh@sina.com
Key Words Bromodomain; Bromodomain and extraterminal domain inhibitor; Colorectal cancer; JAB-8263; MYC; p21
Core Tip Treating with the bromodomain and extraterminal domain (BET) inhibitor JAB-8263, we found that MC38 cells undergo cell cycle arrest and apoptosis. In multiple human colorectal cancer cell lines, we found that JAB-8263 can down-regulate c-MYC expression and up-regulate p21 and p16 expression, associated with highly potent antiproliferative effects of JAB-8263 on colorectal cancer (CRC) cells. The conclusions obtained from in vitro experiments were verified in tumor mouse models that JAB-8263 effectively inhibits CRC growth with acceptable tolerance. Our studies suggested that BET can be a potential effective drug target for suppressing CRC growth, and BET inhibitor JAB-8263 can effectively suppress c-MYC expression and exert anti-tumor activity in CRC models.
Publish Date 2023-02-15 00:44
Citation Liu XM, Xia SY, Long W, Li HJ, Yang GQ, Sun W, Li SY, Du XH. Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models. World J Gastrointest Oncol 2023; 15(2): 332-342
URL https://www.wjgnet.com/1948-5204/full/v15/i2/332.htm
DOI https://dx.doi.org/10.4251/wjgo.v15.i2.332
Full Article (PDF) WJGO-15-332.pdf
Full Article (Word) WJGO-15-332.docx